Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : Extends Tender Offer for Spark Therapeutics

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2019 | 02:02am EST

By Kim Richters

Roche Holding AG said Monday that it has extended the offer period for its planned takeover of biotechnology company Spark Therapeutics to Dec. 16.

Swiss pharmaceutical company Roche said the offer was extended to provide additional time for the U.S. Federal Trade Commission and the U.K. Competition and Markets Authority to complete their reviews of the pending acquisition.

The period for Roche's offer of $114.50 per share has been extended several times and was set to expire on Dec. 10.

As of Dec. 6, around 14.9% of Spark's outstanding shares had been tendered, according to Roche.

Write to Kim Richters at kim.richters@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING AG 2.18% 327.95 Delayed Quote.2.21%
SPARK THERAPEUTICS, INC. 0.00%End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING AG
01/17ROCHE : Invitation to Roche's live audio webcast on efficacy and safety of risdi..
PU
01/14The first earnings season of 2020 starts
01/14Roche aims to 'underwhelm' on SMA drug price to challenge rivals
RE
01/13ILLUMINA : Roche Enter Partnership to Use Genomics for Medical Diagnosis
DJ
01/13Roche and Illumina partner to broaden patient access to genomic testing
GL
01/13EXELIXIS : Outlines Key Priorities and Anticipated Milestones for 2020-21, Annou..
AQ
01/10BRISTOL-MYERS SQUIBB, MACY'S, GRUBHU : Stocks That Defined the Week
DJ
01/10REMINDER : Invitation to Roche's Full Year Results 2019 Presentation
PU
01/09Chugai Announces Global Licensing Agreement with Verastem Oncology for RAF/ME..
AQ
01/07WISETECH GLOBAL LTD (ASX : WTC) Acquires Leading Solutions Provider in Switzerla..
AQ
More news
Financials (CHF)
Sales 2019 62 131 M
EBIT 2019 21 971 M
Net income 2019 14 189 M
Debt 2019 3 214 M
Yield 2019 2,82%
P/E ratio 2019 20,0x
P/E ratio 2020 19,2x
EV / Sales2019 4,56x
EV / Sales2020 4,37x
Capitalization 280 B
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 331,02  CHF
Last Close Price 327,95  CHF
Spread / Highest target 14,3%
Spread / Average Target 0,94%
Spread / Lowest Target -31,4%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG2.21%289 160
JOHNSON & JOHNSON1.60%392 596
MERCK AND COMPANY0.02%231 608
PFIZER3.39%224 187
NOVARTIS-0.29%217 045
BRISTOL-MYERS SQUIBB COMPANY4.03%156 404